Cell therapy (CAR-T)

Your own T cells, modified in the laboratory to recognise the tumour — the field Dr Eleftheriadis trained in at The Christie.

What it is

CAR-T cell therapy is among the most specialised approaches in modern oncology. The patient’s own T cells are collected, genetically modified in the laboratory to recognise a specific target on cancer cells, expanded, and returned to the body.

Dr Eleftheriadis trained in this field as a Clinical Research Fellow at The Christie in Manchester, on the European ATTRACT immuno-oncology programme.

How it is done

Collection — lymphocytes are collected from the blood in a procedure similar to donating blood (apheresis).
Modification — in the laboratory a chimeric antigen receptor (CAR) is introduced, teaching the cells which target to recognise.
Expansion — the modified cells are multiplied to sufficient numbers. This usually takes a few weeks.
Infusion — the cells are returned to the patient, in a specialised centre and under close monitoring.

Who it is for

Approved indications today are mainly in haematological malignancies — certain lymphomas, acute lymphoblastic leukaemia and multiple myeloma — usually after previous lines of treatment.

In solid tumours CAR-T remains a field of intensive research. That means that for most patients with a solid tumour, access today is through clinical trials.

What to expect

The process requires a specialised centre and admission with close monitoring during the first weeks. It is not a same-day treatment: the cells take time to manufacture, and that is factored into planning.

Side effects and management

The two characteristic reactions are cytokine release syndrome and neurological complications. Both are now well recognised, with established management protocols in the centres that perform the procedure.

This is precisely why CAR-T is given only in accredited centres: not because the treatment is unpredictable, but because it needs a team practised at recognising and managing these reactions early.

How the treatment is chosen

None of these treatments is “better” than the others in the abstract. The choice comes from the biology of the specific tumour, the stage, previous treatment, other conditions and — not least — what matters to you.

You will be told why this treatment is proposed rather than another, what it is expected to achieve, and what it will mean in practice for your daily life. If something is unclear, asking is always welcome — and so is a second opinion.

Frequently asked questions

Is CAR-T available for my cancer?

For solid tumours the approved indications remain limited and access is mainly through clinical trials. If you are interested, whether an open trial applies to you can be assessed.

Is it done in Greece?

CAR-T is delivered in specific accredited centres. Eligibility, referral and the approval process are discussed case by case.